It has been established that the anticoagulant edoxaban can regulate thrombosis factors, improve venous lesions, and inhibit venous thrombosis through MMP9-induced PI3K/AKT signaling pathway (Song et al., 2017). This evidence concerns the gene AKT1 and deep vein thrombosis.